IDiyas

For the Inventor, By the Inventor

Tokyo, Japan

Sumio Umezawa

USPTO Granted Patents = 59

Average Co-Inventor Count = 4.6

ph-index = 9

Forward Citations = 311(Granted Patents)

Forward Citations (Not Self Cited) = 257(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Tokyo, JA (1976 - 1978)
  • Shinjuku, JP (1996)
  • Tokyo, JP (1978 - 2001)
  • late of Tokyo, JP (2003)

Company Filing History:

goldMedal48 out of 212 
 
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
 patents
silverMedal4 out of 382 
 
Meiji Seika Kaisha, Ltd.
 patents
bronzeMedal4 out of 329 
 
Yamanouchi Pharmaceutical Company Ltd.
 patents
4. 1 out of 1 
 
Zaidan Hojin Biselbutsu Kagaku Kenkyu Kai (microbial Chemistry Research
 patent
5. 1 out of 589 
 
Kowa Company Limited
 patents
6. 1 out of 2 
 
Meiji Seiki Kaisha, Ltd.
 patents
7. 1 out of 1 
 
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (microbial Chemistry Research
 patent
where one patent can have more than one assignee

Years Active: 1976-2003

Loading Chart...
59 patents (USPTO):
1. 6514946 - Macrolide antibiotics and treatment and prophylaxis of pasteurellosis using the same (2003-02-04),
2. 6184365 - Anthracycline derivatives having 4-amino-2,4,6-trideoxy-2 fluoro-&agr;-L-talopyranosyl group (2001-02-06),
3. 6075135 - 3,4-di-O,N-Protected-4-amino-2,4,6-trideoxy-2-fluoro-L-manno-pyranosyl (2000-06-13),
4. 5958889 - Anthracycline derivatives having (1999-09-28),
5. 5886167 - 2'-deoxy-2'-epi-2'-fluorocoformycin (1999-03-23),
6. 5831072 - Process for the preparation of 2'-deoxy-2'-halocoformycins or (1998-11-03),
7. 5801257 - Anthracycline derivative having a trifluoromethylated sugar (1998-09-01),
8. 5789386 - Fluorine-containing anthracycline derivatives having hydroxyl groups(s) (1998-08-04),
9. 5773607 - Processes for preparing 2'-deoxy-2'-fluorocoformycin and stereoisomers (1998-06-30),
10. 5719130 - Anthracycline derivative having a trifluoromethylated sugar (1998-02-17),
11. 5541303 - 3,4'-dideoxymycaminosltylonolide derivative and process for producing (1996-07-30),
12. 5527781 - 4-O-(aminoglycosyl)- or (1996-06-18),
13. 5101022 - Mycaminosyl tylonolide derivatives (1992-03-31),
14. 5096888 - 3-deoxy mycaminosyl tylonolide derivatives (1992-03-17),
15. 5034517 - Process for producing 2,6-dideoxy-2-fluoro-L-talopyranose (1991-07-23),

Hello! I'm excited to share some fascinating insights about inventor Sumio Umezawa from Tokyo, JP, known for his remarkable contributions to the field of inventions. Let's delve into his impressive journey.

Latest Patents:

Sumio Umezawa has a significant portfolio of 59 patents, with his latest patents focusing on cutting-edge innovations in the medical field. He has disclosed patents related to Macrolide antibiotics, specifically highlighting the treatment and prophylaxis of pasteurellosis using 20,23-disubstituted mycaminosyltylonolide derivatives. These derivatives exhibit selective antibacterial activity against Pasteurella, showcasing Umezawa's pioneering work in pharmaceuticals.

Career Highlights:

Throughout his career, Umezawa has collaborated with renowned companies such as Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai and Meiji Seika Kaisha, Ltd. His tenure with these industry players has been instrumental in driving forward groundbreaking research and development initiatives, solidifying his reputation as a visionary inventor.

Collaborations:

Umezawa has had the pleasure of working alongside esteemed colleagues such as Hamao Umezawa and Tsutomu Tsuchiya. Together, they have synergized their expertise to push the boundaries of innovation, resulting in the creation of impactful inventions that have left a lasting legacy in the scientific community.

In conclusion, Sumio Umezawa's exceptional talent and dedication to pioneering advancements in the field of medicine have positioned him as a trailblazing inventor. His prolific patent portfolio and successful collaborations underscore his invaluable contributions to the realm of innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…